

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

PAR PHARMACEUTICAL, INC.,	:	
PAR STERILE PRODUCTS, LLC,	:	
and ENDO PAR INNOVATION	:	
COMPANY, LLC,	:	
:		
Plaintiffs,	:	
:		
v.	:	Civil Action No. 18-823-CFC
:		
EAGLE PHARMACEUTICALS	:	
INC.,	:	
:		
Defendant.	:	


ORDER

At Wilmington this First day of July, 2019:

Having studied the parties' briefing in connection with the disputed claim terms, D.I. 61, and the intrinsic evidence submitted by the parties, D.I. 62, and having heard oral argument, for the reasons articulated by the Court during the July 1, 2019 *Markman* hearing, the Court adopts the following constructions:

CLAIM TERM	COURT'S CONSTRUCTION
“vasopressin degradation products”	Plain and ordinary meaning, no construction necessary.
#239 patent	
“acetate buffer”	A solution containing a mixture of acetic acid and acetate that is capable of resisting change in pH upon the addition of acidic or basic substances
#223 patent	

CLAIM TERM	COURT'S CONSTRUCTION
"10 mM acetate buffer" #478 patent	A solution containing a mixture of acetic acid and acetate, with a total concentration of 10mM, that is capable of resisting change in pH upon the addition of acidic or basic substances
"administering to the human a unit dosage form" #478 patent and #209 patent	Plain and ordinary meaning; no construction necessary.
"administering the diluted unit dosage form to the human by intravenous administration" #239 patent	Plain and ordinary meaning; no construction necessary.
"intravenously administering the pharmaceutical composition to the human" #526 patent	Plain and ordinary meaning; no construction necessary.
"intravenously administering the portion of the pharmaceutical composition to the human" #223 patent	Plain and ordinary meaning; no construction necessary.
"intravenously administering the second portion of the pharmaceutical composition to the human" #223 patent	Plain and ordinary meaning; no construction necessary.


 CONNOLLY, UNITED STATES DISTRICT JUDGE